Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | BCL9 | O00512 | 1/20 | 0.33 |
| ▸ | CDH1 | P12830 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274363 | 0.89 | KMT2A (0.39) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21274288 | 0.89 | KMT2A (0.39) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21274056 | 0.87 | KMT2A (0.40) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL22822815 | 0.82 | TP53 (0.38) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21274083 | 0.81 | MEN1 (0.40) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21274187 | 0.79 | MAPT (0.40) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21273856 | 0.79 | MAPT (0.40) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21268734 | 0.78 | MAPT (0.39) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21268737 | 0.78 | MAPT (0.39) | MAPTSMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL21281509 | 0.78 | MAPT (0.39) | MAPTSMN1; SMN2MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | claimed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
| CN-112105357-A | Pharmaceutically acceptable 6,5 heterobicyclic derivatives | UCB生物制药有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | MAPT 2459/4885SMN1; SMN2 2435/4885MEN1 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.